frame-graph02ttt01Overall1.800.20.40.60.811.21.41.6PlaceboXyzalP<0.001Improvement in RQLQQoL_Chart1_All_m[1]OverallPlaceboXyzalP<0.0011.800.20.40.60.811.21.41.6Improvement in RQLQ37%improvementvs placebo (P<0.001)Vector Smart ObjectNasalSymptomsEyeSymptoms**PlaceboXyzal*P<0.001;P<0.051.800.20.40.60.811.21.41.6Improvement in RQLQQoL_Chart1_All_m[1]*P<0.001;P<0.05PlaceboXyzalNasalSymptomsEyeSymptoms**1.800.20.40.60.811.21.41.6Improvement in RQLQVector Smart Object2ActivitiesSleepPracticalProblemsEmotional**PlaceboXyzal*P<0.001;P<0.051.800.20.40.60.811.21.41.6Improvement in RQLQQoL_Chart1_All_m[1]ActivitiesSleepPracticalProblemsEmotional**1.800.20.40.60.811.21.41.6*P<0.001;P<0.05PlaceboXyzalImprovement in RQLQttt02Improvement in WPAI-AS Scores20181614121086420Patient Xperience20181614121086420ctaObject1LevocetirizineXyzalvs.LevocetirizineXyzal 5 mgLevocetirizineDextrocetirizineZyrtec 10 mgvs.Xyzal 5 mgLevocetirizineDextrocetirizineZyrtec 10 mgLevocetirizinesymptom-xpert-graph00-desktop-50-40-30-20-100Xyzal(n=240)Xyzal(n=236)!"!#!$!"#$()*+,-./,01-50-40-30-20-100Percent Reduction in MSCS with XyzalXyzal(n=240)Xyzal(n=236)46%reduction vs 11% placebo (n=93) (P<0.001)34% reduction vs 18% placebo (n=95) (P<0.001)Hour 1Hour 24Week 8Mean T4SS Change from BaselineWeek 10-0.5-1-1.5-2-2.5-3-3.5-4PlaceboXyzalVector Smart Object4PlaceboXyzalWeek 1Week 80-0.5-1-1.5-2-2.5-3-3.5-486%Reductionvs placebo(P<0.001)47%Reductionvs placebo(P<0.001)Mean T4SS Change from Baseline0 -0.5 -1 -1.5 -2 -2.5 -3 -3.5 -4symptom-xpert-graph02-desktopWeek 100.20.40.60.81.06 MonthsMean T5SS Change from BaselineXyzalPlacebo6 MonthsWeek 1PlaceboXyzal00.20.40.60.81.06 MonthsMean T5SS Change from BaselineWeek 16 Months00.20.40.60.81.0PlaceboXyzalMean T5SS Change from BaselineWeek 16 MonthsPlaceboXyzal00.20.40.60.81.0Mean T5SS Change from BaselineWeek 16 MonthsPlaceboXyzal00.20.40.60.81.0Mean T5SS Change from BaselineSignificant Reduction in Symptoms14121086420-2-101 25 26 27 28Mean Score (MSCS)24PlaceboXyzal 5 mg (P<0.001)Hours After Drug IntakeSignificant Reduction in Symptoms

For U.S. Healthcare Professionals Only

True 24-Hour Relief That Doesn’t Fade

Significant 24-hour relief with Xyzal (P<0.001)1:

reduction in major symptom complex score (MSCS)

Significant reduction in allergy symptoms

Noticeable symptom relief demonstrated in under 1 hour1

Footnotes & References
x
  • A double-blind, randomized, placebo-controlled three-way cross-over study evaluating one dose of levocetirizine 5 mg vs fexofenadine 120 mg and placebo over 28 hours in patients (N=94) with seasonal allergic rhinitis.
  • Major Symptom Complex Score (MSCS)=sum of rhinorrhea, sneezing, itchy nose and eyes.
  • Reference: 1. Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol. 2005;60(1):24-31.

As effective at hour 24 as it is at hour 1

Significant reduction in symptoms at hour 1 and hour 241:

reduction in MSCS (adjusted mean change from baseline) with Xyzal vs placebo

Percent Reduction in MSCS with Xyzal

  • Hour 1

    34%

    reduction vs

    18% placebo

    (n=95) (P<0.001)

  • Hour 24

    46%

    reduction vs

    11% placebo

    (n=93) (P<0.001)

Footnotes & References
x
  • A double‐blind, placebo‐ and active‐controlled study comparing the efficacy over 2 days of one dose of levocetirizine 5 mg to cetirizine 10 mg in patients (N=570) aged >16 years with seasonal allergic rhinitis due to ragweed pollen.
  • Major Symptom Complex Score (MSCS)=sum of rhinorrhea, sneezing, itchy nose and eyes.
  • Reference: 1. Data on file, sanofi-aventis U.S. LLC.

Significant relief of common allergic rhinitis symptoms

Significant relief of key allergy symptoms1:

mean reduction in total 4-symptom score (T4SS)

  • 86%

    Reduction

    vs placebo

    (P<0.001)

  • 47%

    Reduction

    vs placebo

    (P<0.001)

Symptoms included1:

  • Nasal pruritus
  • Rhinorrhea
  • Ocular pruritus
  • Sneezing
Footnotes & References
x
  • An 8-week, randomized, double-blind, placebo-controlled, multicenter study of patients aged ≥12 years (N=294) measuring the effectiveness of levocetirizine 5 mg/day vs placebo in perennial allergic rhinitis.
  • Total Four-Symptom Score (T4SS)=nasal pruritus, ocular pruritus, rhinorrhoea and sneezing.
  • Reference: 1. Potter PC; Study Group. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy. 2003;58(9):893-899.

Allergy relief that lasts all allergy season long*

Significant symptom relief sustained over 6 months1:

change in total 5-symptom score (T5SS) demonstrated in the first long-term study of patients with persistent allergic rhinitis with Xyzal vs placebo (P<0.001)

39% improvement in overall symptom score vs 27% with placebo (P<0.001)1

*When used as directed.

Footnotes & References
x
  • XPERT was a 6-month, double-blind, placebo-controlled, multicenter, multinational trial of patients (N=551) with persistent rhinitis (as defined by ARIA [Allergic Rhinitis and its Impact on Asthma]) to measure the effects of levocetirizine 5 mg/day on Rhinoconjunctivitis Quality of Life (RQLQ) and on allergic rhinitis symptoms as measured by Total 5 Symptoms Score (T5SS).
  • Total 5 Symptoms Score (T5SS)=rhinorrhea, sneezing, nasal congestion, and nasal and ocular pruritus.
  • Reference: 1. Rogkakou A, Villa E, Garelli V, Canonica GW. Persistent allergic rhinitis and the XPERT study. World Allergy Organ J. 2011;4(suppl 3):S32-S36.